9700_w15_qp_43
A paper of Biology, 9700
Questions:
10
Year:
2015
Paper:
4
Variant:
3

Login to start this paper & get access to powerful tools

1
2
A vaccine, NicVAX, is being developed to help people stop smoking tobacco. Injection of NicVAX into the body causes production of antibody molecules that bind to nicotine. Outline the immune response that leads to the production of these anti-nicotine antibodies. Mice injected with NicVAX produce B-lymphocytes that mature into cells responsible for the production of antibody (plasma cells). Outline how these B-lymphocytes can be used to produce monoclonal antibody. Tobacco smoking during pregnancy has adverse side-effects on the developing fetus. An investigation was carried out to find out whether vaccinating pregnant women with NicVAX might offer some protection for the developing fetus. Two different monoclonal antibodies, produced in response to NicVAX, were used in this investigation: • Nic-IgG • Nic311. Nicotine, or nicotine plus one of the monoclonal antibodies, was injected into the maternal circulation. The concentrations of nicotine in the fetal circulation were measured at intervals. The results of the investigation are shown in Fig 2.1.              WLPHPLQXWHV QLFRWLQHFRQFHQWUDWLRQ LQIHWDOFLUFXODWLRQQJFP²     QLFRWLQH QLFRWLQH  1LF QLFRWLQH  1LFOJ* With reference to , describe the results obtained for nicotine only. Discuss the extent to which these results support the idea that vaccination with NicVAX could protect the developing fetus of a woman who smokes tobacco. State one medical use of monoclonal antibodies, other than their use in producing vaccines.
3
4
Haemophilia A and haemophilia B are common hereditary disorders of blood clotting. Haemophilia A is a sex-linked genetic disorder that affects approximately 1 in 20 000 males worldwide. It is caused by a recessive allele of a gene coding for a clotting factor and results in excessive bleeding. There is currently no cure, but symptoms of haemophilia can be treated with a transfusion of a clotting factor to slow down the bleeding. State how genetic screening could reduce the number of cases of haemophilia. Some genetic disorders can be treated with gene therapy. Outline the aims of gene therapy. Suggest why haemophilia A is a suitable disorder for treatment with gene therapy. Haemophilia A and haemophilia B are caused by mutations in different blood clotting genes, F8 and F9 respectively. Both disorders have been treated with gene therapy involving the use of a vector. Table 4.1 shows the lengths, in kilobases , of the F8 and F9 genes. Table 4.1 haemophilia gene gene length / kb A F8 >8 B F9 1.4 With reference to Table 4.1, suggest why gene therapy using the F9 gene has been more successful than using the F8 gene. Two frequently used vectors in gene therapy are compared in Table 4.2. Table 4.2 feature vector adenovirus retrovirus genetic material of virus double-stranded DNA single-stranded RNA expression of inserted gene high gene expression gene expression in dividing cells only host immune response to virus high low With reference to Table 4.2, explain the advantages and disadvantages of using adenovirus rather than retrovirus as a vector.
5
6
7
8